ArticleEuropean journal of medical research2025
Safety of a higher thiamylal induction dose in pediatric sedation for magnetic resonance imaging scans.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundPrevious studies have shown that 3.6 (2.8-4.0) mg/kg of intravenous thiamylal is effective and safe for pediatric sedation during magnetic resonance imaging (MRI) scans, although its success rate (96.6%) is slightly lower than that via propofol (99%). This retrospective study aimed to evaluate whether a higher induction dose of thiamylal can reduce MRI scan interruptions without increasing the incidence of adverse events.
methodsThis study included patients aged < 18 years who underwent MRI under thiamylal sedation between January 2021 and December 2022. Intravenous atropine (0.01 mg/kg) and midazolam (0.08 mg/kg) were administered as premedications. An induction intravenous dose of 2-5 mg/kg thiamylal was administered, with additional doses administered as needed. The induction dose was defined as the total amount of thiamylal administered before the scan. Once adequate sedation was achieved, MRI was performed. Any additional doses of thiamylal required because of scan interruption were recorded as rescue doses. Patients who received an induction thiamylal dose of < 3.6 mg/kg were categorized into the lower induction dose group. The primary endpoint was the rate of MRI interruptions. Secondary endpoints included adverse events related to sedation, total thiamylal dose, and total MRI scanning time.
resultsA total of 566 patients, with a median age of 56.4 months (range: 24.0-79.2 months) and median weight of 16.0 kg (range: 10.3-21.0 kg), were included in the analysis. The median induction and total dose of thiamylal per body weight were 4.7 (3.8-5.8) mg/kg and 6.0 (4.6-8.1) mg/kg, respectively. No respiratory or other adverse events were recorded. For 30- to 60-min MRI scans, the higher induction dose group had a lower scan interruption rate, and a lower total thiamylal dose was required than that for the lower induction dose group.
conclusionA higher induction dose of thiamylal (5.4 ± 1.6 mg/kg) is safe and is associated with a reduced scan interruption rate for 30- to 60-min MRI scans, as well as a lower total thiamylal dose requirement. However, thiamylal is not an ideal sedative agent for MRI scans longer than 1 h.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.